- Home
- CALC vs PMN Comparison
CALC vs PMN Comparison
Compare CALC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- PMN
- Stock Information
- Founded
- CALC 2011
- PMN 2004
- Country
- CALC United States
- PMN Canada
- Employees
- CALC N/A
- PMN N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- CALC Health Care
- PMN Health Care
- Exchange
- CALC Nasdaq
- PMN Nasdaq
- Market Cap
- CALC 22.9M
- PMN 16.0M
- IPO Year
- CALC N/A
- PMN N/A
- Fundamental
- Price
- CALC $2.13
- PMN $0.40
- Analyst Decision
- CALC Strong Buy
- PMN Strong Buy
- Analyst Count
- CALC 2
- PMN 2
- Target Price
- CALC $14.50
- PMN $4.50
- AVG Volume (30 Days)
- CALC 38.7K
- PMN 63.7K
- Earning Date
- CALC 08-11-2025
- PMN 08-07-2025
- Dividend Yield
- CALC N/A
- PMN N/A
- EPS Growth
- CALC N/A
- PMN N/A
- EPS
- CALC N/A
- PMN N/A
- Revenue
- CALC N/A
- PMN N/A
- Revenue This Year
- CALC N/A
- PMN N/A
- Revenue Next Year
- CALC N/A
- PMN N/A
- P/E Ratio
- CALC N/A
- PMN N/A
- Revenue Growth
- CALC N/A
- PMN N/A
- 52 Week Low
- CALC $1.42
- PMN $0.38
- 52 Week High
- CALC $5.97
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- CALC 48.14
- PMN 32.23
- Support Level
- CALC $1.59
- PMN $0.48
- Resistance Level
- CALC $1.69
- PMN $0.50
- Average True Range (ATR)
- CALC 0.15
- PMN 0.03
- MACD
- CALC 0.01
- PMN -0.01
- Stochastic Oscillator
- CALC 46.51
- PMN 18.75
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.